Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.

Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE.

Anticancer Res. 2011 Dec;31(12):4135-9.

PMID:
22199271
2.
3.

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

Olaussen KA, Mountzios G, Soria JC.

Curr Opin Pulm Med. 2007 Jul;13(4):284-9. Review.

PMID:
17534174
4.

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB.

Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Review.

PMID:
18804893
5.
6.

Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.

Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B.

Cancer Control. 2003 Jul-Aug;10(4):297-305. Review.

PMID:
12915808
7.

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.

Bišof V, Zajc Petranović M, Rakušić Z, Samardžić KR, Juretić A.

Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2305-17. doi: 10.1007/s00405-015-3710-x. Epub 2015 Jul 16. Review.

PMID:
26179868

Supplemental Content

Support Center